Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

NEW YORK, N.Y. – Pfizer Inc. on Monday released detailed analyses of myocarditis cases linked to its COVID-19 vaccine, ...

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety ...

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...

May Parsons became the first person in the world to deliver the COVID-19 vaccine outside of a clinical trial at University ...

Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

French vaccine developer Valneva is closing down a site that houses both operational and R&D work, impacting 30 employee roles. | French vaccine maker Valneva is closing down a site that houses both ...

COVID-19 risk might be much lower than in past summers, but it’s not gone - making a pre-Christmas booster for some a good ...

Shares of Moderna and BioNTech fell on Monday, likely in response to a FDA official's memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children. Concern about that ...